Related references
Note: Only part of the references are listed.Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2011)
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
Kathryn Beal et al.
RADIATION ONCOLOGY (2011)
Adnectins: engineered target-binding protein therapeutics
D. Lipovsek
PROTEIN ENGINEERING DESIGN & SELECTION (2011)
Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis (vol 27, pg 4211, 2009)
Laurent
JOURNAL OF CLINICAL ONCOLOGY (2010)
Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Current Therapeutic Paradigms in Glioblastoma
Allison Quick et al.
REVIEWS ON RECENT CLINICAL TRIALS (2010)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
Walid S. Kamoun et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer
Elizabeth R. Gerstner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells
Naoki Oka et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Exogenous control of mammalian gene expression via modulation of translational termination
George J. Murphy et al.
NATURE MEDICINE (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man
ME Baldwin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
